- The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United StatesPhil McEwan
Centre for Health Economics, Swansea University, Wales, UK Health Economics and Outcomes Research Ltd, Wales, UK
Hepatology 58:54-64. 2013..5 billion and 59,035 fewer HCV-related complications. Total QALYs and complications avoided are maximized when treatment initiation occurs as soon as possible after testing...
- Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH modelPhil McEwan
Centre for Health Economics, Swansea University, Wales, UK
Appl Health Econ Health Policy 11:53-63. 2013..Treatment response is highly dependent upon the extent of liver fibrosis yet there is little evidence quantifying the cost effectiveness of RGT particularly conditional upon fibrosis stage...
- Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis CRebecca Townsend
Cardiff Research Consortium, Cardiff, Wales, UK
Value Health 14:1068-77. 2011..This study aimed to review structural frameworks and key model parameters as reported in current economic evaluations for treatments for chronic hepatitis C, and model the impact of variability across parameters on results...